Literature DB >> 19660011

Is there any relationship between actual benefit and added value of drugs and pharmacovigilance alerts?

Neda Tavassoli, Jean-Louis Montastruc.   

Abstract

Mesh：

Year:  2009        PMID： 19660011      PMCID： PMC2732948          DOI： 10.1111/j.1365-2125.2009.03403.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  3 in total

1.  A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.

Authors:  Peter G M Mol; Sabine M J M Straus; Sigrid Piening; Jonie T N de Vries; Pieter A de Graeff; Flora M Haaijer-Ruskamp
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

2.  Post-approval safety issues with innovative drugs: a European cohort study.

Authors:  Peter G M Mol; Arna H Arnardottir; Domenico Motola; Patrick J Vrijlandt; Ruben G Duijnhoven; Flora M Haaijer-Ruskamp; Pieter A de Graeff; Petra Denig; Sabine M J M Straus
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

3.  Methods in clinical pharmacology.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.